AR075344A1 - Derivados heterociclicos nitrogenados fusionados, medicamentos que los contienen y uso de los mismos en el tratamiento de enfermedades cardiacas, renales y metabolicas, entre otras - Google Patents
Derivados heterociclicos nitrogenados fusionados, medicamentos que los contienen y uso de los mismos en el tratamiento de enfermedades cardiacas, renales y metabolicas, entre otrasInfo
- Publication number
- AR075344A1 AR075344A1 ARP100100240A ARP100100240A AR075344A1 AR 075344 A1 AR075344 A1 AR 075344A1 AR P100100240 A ARP100100240 A AR P100100240A AR P100100240 A ARP100100240 A AR P100100240A AR 075344 A1 AR075344 A1 AR 075344A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- alkyl
- hydrogen atom
- alkoxy
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Derivados heterocíclicos nitrogenados fusionados, con actividad antagonista del receptor de angiotensina II y una actividad agonista del receptor y activado por el proliferador de peroxisomas y es de utilidad como un agente para la prevencion o el tratamiento de enfermedades circulatorias tales como hipertension, y similares y/o enfermedades metabolicas tales como diabetes, y similares, y otros. Reivindicacion 1: Un compuesto caracterizado por la formula (1): en donde R1 es un átomo de hidrogeno, un alquilo C1-6 opcionalmente sustituido, un grupo cíclico no aromático de 3 a 10 miembros opcionalmente sustituido o un grupo cíclico aromático de 5 o 6 miembros opcionalmente sustituido, R2 es un átomo de hidrogeno, un alquilo C1-6 opcionalmente sustituido, un alcoxi C1-6 opcionalmente sustituido, un alquil C1-6-tio opcionalmente sustituido, un alquil C1-6-sulfinilo opcionalmente sustituido o un alquil C1-6-sulfonilo opcionalmente sustituido, R3 es un átomo de hidrogeno, un átomo de halogeno, un alquilo C1-6 opcionalmente sustituido o un alcoxi C1-6 opcionalmente sustituido, X, Y y Z son cada uno, de modo independiente, un átomo de nitrogeno o CR4, en donde R4 es un átomo de hidrogeno, un átomo de halogeno, un alquilo C1-6 opcionalmente sustituido, un alcoxi C1-6 opcionalmente sustituido o un cicloalquilo C3-6 opcionalmente sustituido, W es un alquileno C1-4 opcionalmente sustituido, -O-W'-, -W'-O-, -N(Ra)-W'- o -W'-N(Ra)-, en donde W' es un enlace o un alquileno C1-4 opcionalmente sustituido, Ra es un átomo de hidrogeno, un alquilo C1-6 opcionalmente sustituido o un cicloalquilo C3-6 opcionalmente sustituido, A es un anillo aromático divalente de 5 o 6 miembros opcionalmente sustituido y B es un acilo o un grupo heterocíclico de 3 a 10 miembros opcionalmente sustituido, siempre que, si B es un carboxi, un carbamoilo o un tetrazolilo, R1 no sea un átomo de hidrogeno, o una de sus sales.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009020720 | 2009-01-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR075344A1 true AR075344A1 (es) | 2011-03-23 |
Family
ID=42026435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100100240A AR075344A1 (es) | 2009-01-30 | 2010-01-29 | Derivados heterociclicos nitrogenados fusionados, medicamentos que los contienen y uso de los mismos en el tratamiento de enfermedades cardiacas, renales y metabolicas, entre otras |
Country Status (37)
| Country | Link |
|---|---|
| US (4) | US8592431B2 (es) |
| EP (1) | EP2384327B1 (es) |
| JP (2) | JP4892649B1 (es) |
| KR (1) | KR20110113758A (es) |
| CN (2) | CN103788097B (es) |
| AR (1) | AR075344A1 (es) |
| AU (1) | AU2010208863A1 (es) |
| CA (1) | CA2750710C (es) |
| CL (1) | CL2011001848A1 (es) |
| CO (1) | CO6362011A2 (es) |
| CR (1) | CR20110463A (es) |
| CY (1) | CY1114530T1 (es) |
| DK (1) | DK2384327T3 (es) |
| DO (1) | DOP2011000249A (es) |
| EA (1) | EA019823B1 (es) |
| EC (1) | ECSP11011294A (es) |
| ES (1) | ES2433225T3 (es) |
| GE (1) | GEP20135961B (es) |
| HK (1) | HK1162505A1 (es) |
| HR (1) | HRP20131017T1 (es) |
| IL (1) | IL214283A0 (es) |
| MA (1) | MA33071B1 (es) |
| ME (1) | ME01621B (es) |
| MX (1) | MX2011008058A (es) |
| MY (1) | MY152946A (es) |
| NZ (1) | NZ594606A (es) |
| PE (1) | PE20120593A1 (es) |
| PL (1) | PL2384327T3 (es) |
| PT (1) | PT2384327E (es) |
| RS (1) | RS53012B (es) |
| SG (1) | SG173135A1 (es) |
| SI (1) | SI2384327T1 (es) |
| TN (1) | TN2011000368A1 (es) |
| TW (2) | TWI468410B (es) |
| UY (1) | UY32409A (es) |
| WO (1) | WO2010087515A1 (es) |
| ZA (1) | ZA201105867B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2384327T3 (pl) | 2009-01-30 | 2013-12-31 | Takeda Pharmaceuticals Co | Związki ze skondensowanym pierścieniem i ich zastosowanie |
| PL2655375T3 (pl) | 2010-12-23 | 2015-05-29 | Sanofi Sa | Pochodne pirymidynonu, ich wytwarzanie i ich farmaceutyczne zastosowanie |
| CZ304252B6 (cs) * | 2011-04-11 | 2014-01-29 | Zentiva, K. S. | Způsob výroby 2-ethoxy-1-((2´-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)bifenyl-4-yl)methyl)-1H-benzo[d]imidazol-7-karboxylátů a jejich převedení na azilsartan |
| CN109563100B (zh) | 2016-06-20 | 2021-08-27 | 诺华股份有限公司 | 三唑并嘧啶化合物的晶体形式 |
| CN111107744A (zh) | 2017-09-26 | 2020-05-05 | 埃科莱布美国股份有限公司 | 酸性/阴离子抗微生物组合物和杀病毒组合物以及其用途 |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
| TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
| US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
| US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
| KR20220064369A (ko) | 2019-08-14 | 2022-05-18 | 인사이트 코포레이션 | Cdk2 저해제로서의 이미다졸릴 피리디미딘일아민 화합물 |
| BR112022006977A2 (pt) | 2019-10-11 | 2022-09-20 | Incyte Corp | Aminas bicíclicas como inibidores de cdk2 |
| CN112745319B (zh) * | 2019-10-30 | 2022-06-17 | 中国科学院上海药物研究所 | 一类取代三环结构的化合物、其制备方法及用途 |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2672892B1 (fr) | 1991-02-20 | 1994-01-14 | Synthelabo | Derives de 4-pyrimidinones, leur preparation et leur application en therapeutique. |
| US5472967A (en) | 1991-02-20 | 1995-12-05 | Synthelabo | 4-pyrimidinone derivatives their preparation and their application in therapy |
| IL102183A (en) | 1991-06-27 | 1999-11-30 | Takeda Chemical Industries Ltd | The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them |
| TW251288B (es) * | 1991-06-27 | 1995-07-11 | Takeda Dharm Industry Co Ltd | |
| IT1250749B (it) | 1991-08-02 | 1995-04-21 | Luso Farmaco Inst | Composti eterociclici ad attivita' a ii antagonista |
| US5389632A (en) | 1992-02-24 | 1995-02-14 | Laboratoires Upsa | Pyrazolopyrimidine derivatives which are angiotensin II receptor antagonists |
| FR2687677B1 (fr) * | 1992-02-24 | 1996-10-11 | Union Pharma Scient Appl | Nouveaux derives de polyazaindenes antagonistes des recepteurs a l'angiotensine ii ; leurs procedes de preparation, compositions pharmaceutiques les contenant. |
| US5387747A (en) | 1992-02-24 | 1995-02-07 | Laboratoires Upsa | Triazolopyrimidine derivatives which are angiotensin II receptor antagonists, their methods of preparation and pharmaceutical compositions in which they are present |
| IT1263804B (it) | 1993-01-22 | 1996-09-03 | Luso Farmaco Inst | Derivati pirimidinonici fusi con eterocicli azotati ad attivita' a ii antagonista |
| GB9406573D0 (en) | 1994-03-31 | 1994-05-25 | Merck Sharp & Dohme | Medicaments |
| WO1996040256A1 (en) | 1995-06-07 | 1996-12-19 | G.D. Searle & Co. | Method to treat cardiofibrosis with a combination of an angiotensin ii antagonist and spironolactone |
| JPH11507627A (ja) | 1995-06-07 | 1999-07-06 | ジー．ディー．サール アンド カンパニー | 充血性心不全症を処置するためのエポキシ−ステロイド系アルドステロン拮抗物質とアンギオテンシンｉｉ拮抗物質との組合せ治療 |
| ATE216261T1 (de) | 1995-06-07 | 2002-05-15 | Searle & Co | Kombinationstherapie zur behandlung des kongestiven herzversagens mit spironolacton und angiotensin ii-antagonist |
| WO1996040255A2 (en) | 1995-06-07 | 1996-12-19 | G.D. Searle & Co. | Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldosterone antagonist |
| FR2812876B1 (fr) * | 2000-08-08 | 2002-09-27 | Galderma Res & Dev | Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques |
| SE0101579D0 (sv) | 2001-05-04 | 2001-05-04 | Astrazeneca Ab | New compounds |
| US7232828B2 (en) | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
| TW200418835A (en) | 2003-01-24 | 2004-10-01 | Tanabe Seiyaku Co | A pyrazolopyrimidine compound and a process for preparing the same |
| US20050065184A1 (en) | 2003-08-29 | 2005-03-24 | Aaipharma Inc. | Method of reducing the risk of oxidative stress |
| JP2007520559A (ja) * | 2004-02-03 | 2007-07-26 | アボット・ラボラトリーズ | 治療薬としてのアミノベンゾオキサゾール類 |
| GEP20105024B (en) | 2004-06-02 | 2010-06-25 | Takeda Pharmaceuticals Co | Fused heterocyclic compound |
| RU2384346C2 (ru) | 2004-06-23 | 2010-03-20 | Зольвай Фармасьютиклз Гмбх | Фармацевтические композиции, содержащие nep-ингибиторы, ингибиторы эндогенной эндотелинпродуцирующей системы и антагонисты at1-рецептора |
| US20050288272A1 (en) | 2004-06-23 | 2005-12-29 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists |
| WO2007013078A2 (en) | 2005-07-27 | 2007-02-01 | Mor Research Applications Ltd. | Inhibition of the renin-angiotensin system for the treatment of renal, vascular and cartilage pathology |
| WO2007053406A1 (en) | 2005-10-28 | 2007-05-10 | Novartis Ag | Combinations of antihypertensive and cholesterol lowering agents |
| WO2007051007A2 (en) | 2005-10-28 | 2007-05-03 | Novartis Ag | Combination of antihypertensives with cholesterol-lowering agent |
| US20080064871A1 (en) | 2006-05-26 | 2008-03-13 | Japan Tobacco Inc. | Production Method of Nitrogen-Containing Fused Ring Compounds |
| AU2007319505A1 (en) | 2006-11-09 | 2008-05-22 | Ore Pharmaceuticals Inc. | Breast cancer screening and treatment methods |
| US20090012052A1 (en) * | 2006-11-09 | 2009-01-08 | Ore Pharmaceuticals Inc. | Method for treating er+ breast cancer |
| BRPI0719060A2 (pt) * | 2006-11-24 | 2014-02-04 | Takeda Pharmaceutical | Composto, prodroga, agente farmacêutico, métodos para inibir um receptor de angiotensina ii e/ou ativar um receptor ativado com proliferador de peroxisoma, e para prevenir ou tratar doenças ou condições, e, uso de um composto |
| EP2253630A1 (en) | 2007-05-21 | 2010-11-24 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| CA2703019A1 (en) | 2007-09-20 | 2009-03-26 | University Of Rochester | Method and compositions for treatment or prevention of inflammatory conditions |
| PT2268612E (pt) | 2008-03-24 | 2014-11-13 | Novartis Ag | Inibidores de metaloprotease de matriz à base de arilsulfonamidas |
| WO2009137465A2 (en) | 2008-05-05 | 2009-11-12 | University Of Rochester | Methods and compositions for the treatment or prevention of pathological cardiac remodeling and heart failure |
| PL2384327T3 (pl) | 2009-01-30 | 2013-12-31 | Takeda Pharmaceuticals Co | Związki ze skondensowanym pierścieniem i ich zastosowanie |
-
2010
- 2010-01-29 PL PL10703532T patent/PL2384327T3/pl unknown
- 2010-01-29 EP EP10703532.1A patent/EP2384327B1/en active Active
- 2010-01-29 ME MEP-2013-131A patent/ME01621B/me unknown
- 2010-01-29 GE GEAP201012358A patent/GEP20135961B/en unknown
- 2010-01-29 TW TW99102537A patent/TWI468410B/zh not_active IP Right Cessation
- 2010-01-29 AR ARP100100240A patent/AR075344A1/es unknown
- 2010-01-29 CN CN201310750040.3A patent/CN103788097B/zh not_active Expired - Fee Related
- 2010-01-29 RS RS20130472A patent/RS53012B/en unknown
- 2010-01-29 ES ES10703532T patent/ES2433225T3/es active Active
- 2010-01-29 PT PT107035321T patent/PT2384327E/pt unknown
- 2010-01-29 AU AU2010208863A patent/AU2010208863A1/en not_active Abandoned
- 2010-01-29 KR KR1020117020049A patent/KR20110113758A/ko not_active Application Discontinuation
- 2010-01-29 MX MX2011008058A patent/MX2011008058A/es active IP Right Grant
- 2010-01-29 TW TW103125956A patent/TW201444848A/zh unknown
- 2010-01-29 MA MA34132A patent/MA33071B1/fr unknown
- 2010-01-29 US US13/146,989 patent/US8592431B2/en not_active Expired - Fee Related
- 2010-01-29 UY UY0001032409A patent/UY32409A/es not_active Application Discontinuation
- 2010-01-29 SG SG2011053741A patent/SG173135A1/en unknown
- 2010-01-29 CN CN201080014441.7A patent/CN102369205B/zh not_active Expired - Fee Related
- 2010-01-29 CA CA2750710A patent/CA2750710C/en not_active Expired - Fee Related
- 2010-01-29 MY MYPI2011003554 patent/MY152946A/en unknown
- 2010-01-29 US US12/696,147 patent/US8283353B2/en not_active Expired - Fee Related
- 2010-01-29 DK DK10703532.1T patent/DK2384327T3/da active
- 2010-01-29 JP JP2011525329A patent/JP4892649B1/ja not_active Expired - Fee Related
- 2010-01-29 SI SI201030403T patent/SI2384327T1/sl unknown
- 2010-01-29 NZ NZ594606A patent/NZ594606A/xx not_active IP Right Cessation
- 2010-01-29 PE PE2011001418A patent/PE20120593A1/es not_active Application Discontinuation
- 2010-01-29 WO PCT/JP2010/051651 patent/WO2010087515A1/en active Application Filing
- 2010-01-29 EA EA201101138A patent/EA019823B1/ru not_active IP Right Cessation
-
2011
- 2011-06-30 JP JP2011146858A patent/JP5676379B2/ja not_active Expired - Fee Related
- 2011-07-25 IL IL214283A patent/IL214283A0/en unknown
- 2011-07-27 TN TN2011000368A patent/TN2011000368A1/fr unknown
- 2011-07-29 CL CL2011001848A patent/CL2011001848A1/es unknown
- 2011-07-29 DO DO2011000249A patent/DOP2011000249A/es unknown
- 2011-08-09 US US13/205,967 patent/US8921379B2/en not_active Expired - Fee Related
- 2011-08-11 ZA ZA2011/05867A patent/ZA201105867B/en unknown
- 2011-08-26 CR CR20110463A patent/CR20110463A/es unknown
- 2011-08-29 CO CO11109923A patent/CO6362011A2/es active IP Right Grant
- 2011-08-30 EC EC2011011294A patent/ECSP11011294A/es unknown
-
2012
- 2012-03-27 HK HK12103030.2A patent/HK1162505A1/xx not_active IP Right Cessation
-
2013
- 2013-10-22 US US14/059,868 patent/US9115136B2/en not_active Expired - Fee Related
- 2013-10-25 CY CY20131100941T patent/CY1114530T1/el unknown
- 2013-10-25 HR HRP20131017AT patent/HRP20131017T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR075344A1 (es) | Derivados heterociclicos nitrogenados fusionados, medicamentos que los contienen y uso de los mismos en el tratamiento de enfermedades cardiacas, renales y metabolicas, entre otras | |
| PE20091818A1 (es) | DERIVADOS POLISUSTITUIDOS DE 2-ARIL-6-FENIL-IMIDAZO[1,2-a] PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA | |
| PE20181269A1 (es) | Agonistas del receptor de apelina y metodos de uso | |
| CL2013001558A1 (es) | El uso de compuestos moduladores o agonistas de los receptores de s1p para disminuir la frecuencia cardiaca en aproximadamente 2 latidos/minuto; metodo para aminorar, prevenir o limitar un efecto cronotropico negativo; un kit farmaceutico. | |
| PE20142301A1 (es) | Uracilos sustituidos biciclicamente y uso de los mismos | |
| AR074002A1 (es) | Pirazolo e imidazopiridinilpirimidinaminas como inhibidores de la tirosina kinasa (igr-ir) | |
| PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
| PE20120578A1 (es) | Agonistas y antagonistas del receptor de s1p5, y metodos de uso de los mismos | |
| PE20110028A1 (es) | Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato | |
| SI2989100T1 (en) | NAFTIRIDINE DERIVATIVES USED AS ANTAGONISTS INTEGRITY OF ALFA-V-BETA-6 | |
| PH12014502570A1 (en) | Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma] | |
| AR059957A1 (es) | DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER. | |
| CR9459A (es) | Derivados benzodioxano y benzodioxolano y usos de los mismos | |
| PE20150230A1 (es) | Nuevos diazaespirocicloalcanos y azaespirocicloalcanos | |
| AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
| AR062510A1 (es) | Derivados de piridona con actividad antagonista de mch y medicamentos que comprenden estos compuestos | |
| ES2531009T3 (es) | Análogos sustituidos de dicetopiperazina para su uso como agentes para la administración de fármacos | |
| PE20061150A1 (es) | Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1) | |
| AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
| UY31127A1 (es) | Ligandos de oxiadazol del receptor metabotropico para el glutamato y su utilizacion como potenciadores - 841 | |
| PE20080706A1 (es) | Arilmidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina | |
| AR060914A1 (es) | Derivados de furopiridina como ligandos receptores de la acetilcolina nicotinica, una composicion farmaceutica que los comprende y su empleo en la manufactura de un medicamento para el tratamiento de una enfermedad mediada por la activacion del receptor alfa7-nicotinico. | |
| UY29184A1 (es) | Derivados de sulfonilbencimidazol | |
| PE20140968A1 (es) | Derivados de benzamida sustituida | |
| PE20090622A1 (es) | Nuevos derivados de bencimidazol sustituido |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |